Food Allergy Market Expected to Experience Accelerated Growth and Market Evolution by 2036 - DelveInsight | Novartis, Roche, ARS Pharma, ALK Abello, Alfresa Pharma, Stallergenes Greer, DBV Techno

The Key Food Allergy Companies in the market include - Novartis, Roche, ARS Pharmaceuticals, ALK Abello, Alfresa Pharma, Stallergenes Greer, DBV Technologies, Aravax, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others.

DelveInsight's "Food Allergy Market Insights, Epidemiology, and Market Forecast-2036 report offers an in-depth understanding of the Food Allergy, historical and forecasted epidemiology as well as the Food Allergy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

Get a Free sample for the Food Allergy Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/food-allergy-market-insights [https://www.delveinsight.com/report-store/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Food Allergy Market Report:

*
The food allergy market size was valued at around USD 3,500 million in 2025 and is expected to reach approximately USD 10,500 million by 2036, expanding at a CAGR of 9% during the forecast period from 2026 to 2036.

*
In February 2026, Aquestive Therapeutics announced that it received a Complete Response Letter (CRL) from the FDA on January 30, 2026, for the New Drug Application (NDA) seeking approval of ANAPHYLM (dibutepinephrine) Sublingual Film for the treatment of Type I allergic reactions, including anaphylaxis, in patients weighing 30kg or more (approximately 66 pounds).

*
In February 2026, according to Novartis' Q4 2025 presentation, initiation of the Phase III program for remibrutinib is anticipated in the second half of 2026.

*
In August 2025, Stallergenes Greer announced to voluntarily discontinue PALFORZIA by July 31, 2026, not due to safety, quality, or efficacy concerns. The company will fulfill regulatory obligations and support a smooth transition for patients and healthcare providers.

*
In March 2025, DBV Technologies reached an understanding with the US Food and Drug Administration (FDA) based on written responses to its Type D Investigational New Drug (IND) meeting request. The FDA concurred with DBV's proposal that safety exposure data from the VITESSE Phase III study of the Viaskin Peanut Patch in children aged 4-7 years would be sufficient to support BLA filing for this age group, thereby accelerating the anticipated timeline for BLA submission to the first half of 2026.

*
In March 2025, the US FDA approved NEFFY for the treatment of Type I allergic reactions, including anaphylaxis, in children who are aged 4 years and older and weigh 15 to 35 years.

*
In February 2025, researchers at Imperial College's National Heart & Lung Institute (NHLI) shared promising results from the initial phase of clinical trials for a novel peanut allergy vaccine. Working alongside industry partner Allergy Therapeutics, the Imperial team developed the vaccine using virus-like particle (VLP) technology to deliver the peanut allergen protein Ara h2. According to their recent publication in the Journal of Allergy and Clinical Immunology (JACI), the Phase 1 first-in-human trial confirmed the vaccine's safety and tolerability, showing no allergic reactions during skin prick tests when compared to control treatments.

*
At present, omalizumab (XOLAIR), epinephrine nasal spray (NEFFY), and peanut allergen powder (PALFORZIA) are among the approved therapies providing key treatment options for food allergy patients. However, Stallergenes Greer has announced that it will discontinue the commercialization of PALFORZIA effective July 31, 2026, a decision unrelated to the product's safety, efficacy, or quality.

*
According to DelveInsight's estimates, the total diagnosed prevalent cases of Food Allergy in the 7MM were approximately 61,000,000 in 2025.

*
Among the EU4 and the UK, Spain accounted for the highest number of diagnosed prevalent cases of Food Allergy, followed by Germany, whereas France accounted for the lowest number of cases in 2025.

*
In 2025, among gender-specific cases of food allergy in 7 million individuals, males accounted for 53% while females made up 47%.

*
In Japan in 2025, egg allergy had the highest diagnosed prevalence among food allergens, followed by milk allergy, while fish allergy had the lowest prevalence.

*
Key Food Allergy Companies: Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others

*
Key Food Allergy Therapies: Omalizumab (XOLAIR), Epinephrine /Adrenaline (NEFFY/ EURNEFFY), Peanut allergen powder-dnfp (PALFORZIA), Viaskin (DBV712) Peanut Patch, PVX108 (AVX-201), Palforzia, Ligelizumab, Viaskin Peanut, INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others

*
The Food Allergy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Food Allergy pipeline products will significantly revolutionize the Food Allergy market dynamics.

Food Allergy Overview

A food allergy develops when the immune system identifies a particular food as harmful and responds by triggering symptoms, which is known as an allergic reaction. These allergic reactions are caused by allergens, which are specific foods that induce immune responses in susceptible individuals.

To Know in detail about the Food Allergy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Food Allergy Market Forecast [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Food Allergy Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Food Allergy Epidemiology Segmentation:

The Food Allergy market report proffers epidemiological analysis for the study period 2022-2036 in the 7MM segmented into:

*
Total Diagnosed Prevalent Cases of Food Allergy

*
Allergen-specific Diagnosed Prevalent Cases of Food Allergy

*
Gender-Specific Diagnosed Prevalent Cases of Food Allergy

*
Severity-specific Diagnosed Prevalent Cases of Food Allergy

*
Total treated cases of Food Allergy

Download the report to understand which factors are driving Food Allergy epidemiology trends @ Food Allergy Epidemiology Forecast [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Food Allergy Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Food Allergy market or expected to get launched during the study period. The analysis covers Food Allergy market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Food Allergy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Food Allergy Therapies and Key Companies

*
Omalizumab (XOLAIR): Novartis/ Roche

*
Epinephrine /Adrenaline (NEFFY/ EURNEFFY): ARS Pharmaceuticals /ALK Abello /Alfresa Pharma

*
Peanut allergen powder-dnfp (PALFORZIA): Stallergenes Greer

*
Viaskin (DBV712) Peanut Patch: DBV Technologies

*
PVX108 (AVX-201): Aravax

*
INT301: Intrommune Therapeutics

*
AIMab7195: Xencor

*
VE416: Vedanta Biosciences

*
ADP101: Alladapt Immunotherapeutics

*
PVX-108: Aravax

*
Dupilumab: Regeneron

*
DBV 135: DBV Technologies

*
Ligelizumab: Novartis AG

*
CA002: Camallergy

*
Omalizumab: Genentech

*
GI 301: GI Innovation

Discover more about therapies set to grab major Food Allergy market share @ Food Allergy Treatment Landscape [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Food Allergy Market Drivers

*
Rising Prevalence of Food Allergies: The increasing incidence of food allergies among children and adults worldwide is a major factor driving market growth.

*
Growing Awareness and Diagnosis Rates: Improved awareness regarding allergic reactions and advancements in diagnostic testing are leading to earlier and more accurate diagnosis of food allergies.

*
Advancements in Immunotherapy Treatments: The development of oral immunotherapy, biologics, and desensitization therapies is expanding treatment options for food allergy patients.

*
Increasing Demand for Emergency Allergy Medications: Growing use of epinephrine auto-injectors and antihistamine therapies is supporting market expansion.

*
Strong Pipeline Development: Ongoing clinical trials and increased investments in allergy-focused research are accelerating the introduction of innovative therapies.

Food Allergy Market Barriers

*
High Cost of Advanced Therapies: Innovative biologics and immunotherapy treatments can be expensive, limiting affordability for many patients.

*
Limited Curative Treatment Options: Most currently available therapies focus on symptom management rather than providing a permanent cure for food allergies.

*
Risk of Severe Allergic Reactions: Concerns regarding anaphylaxis and adverse reactions during immunotherapy may impact treatment adoption.

*
Stringent Regulatory Requirements: Complex clinical trial and regulatory approval processes may delay the commercialization of new food allergy therapies.

*
Underdiagnosis in Developing Regions: Limited awareness, inadequate healthcare infrastructure, and lack of specialized allergy testing facilities may hinder diagnosis and treatment in emerging markets.

Scope of the Food Allergy Market Report

*
Study Period: 2022-2036

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Food Allergy Companies: Novartis, Roche, ARS Pharmaceuticals, ALK Abello, Alfresa Pharma, Stallergenes Greer, DBV Technologies, Aravax, Aimmune Therapeutics, Inc., Novartis Pharmaceuticals, DBV Technologies, Intrommune Therapeutics, Xencor, Vedanta Biosciences, Alladapt Immunotherapeutics, Aravax, Regeneron, DBV Technologies, Novartis AG, Camallergy, Genentech, GI Innovation, and others

*
Key Food Allergy Therapies: Omalizumab (XOLAIR), Epinephrine /Adrenaline (NEFFY/ EURNEFFY), Peanut allergen powder-dnfp (PALFORZIA), Viaskin (DBV712) Peanut Patch, PVX108 (AVX-201), Palforzia, Ligelizumab, Viaskin Peanut, INT301, AIMab7195, VE416, ADP101, PVX-108, Dupilumab, DBV 135, Ligelizumab, CA002, Omalizumab, GI 301, and others

*
Food Allergy Therapeutic Assessment: Food Allergy current marketed and Food Allergy emerging therapies

*
Food Allergy Market Dynamics: Food Allergy market drivers and Food Allergy market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Food Allergy Unmet Needs, KOL's views, Analyst's views, Food Allergy Market Access and Reimbursement

To know more about Food Allergy companies working in the treatment market, visit @ Food Allergy Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/food-allergy-market-insights?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Food Allergy Market Report Introduction

2. Executive Summary for Food Allergy

3. SWOT analysis of Food Allergy

4. Food Allergy Patient Share (%) Overview at a Glance

5. Food Allergy Market Overview at a Glance

6. Food Allergy Disease Background and Overview

7. Food Allergy Epidemiology and Patient Population

8. Country-Specific Patient Population of Food Allergy

9. Food Allergy Current Treatment and Medical Practices

10. Food Allergy Unmet Needs

11. Food Allergy Emerging Therapies

12. Food Allergy Market Outlook

13. Country-Wise Food Allergy Market Analysis (2022-2036)

14. Food Allergy Market Access and Reimbursement of Therapies

15. Food Allergy Market Drivers

16. Food Allergy Market Barriers

17. Food Allergy Appendix

18. Food Allergy Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=food-allergy-market-expected-to-experience-accelerated-growth-and-market-evolution-by-2036-delveinsight-novartis-roche-ars-pharma-alk-abell-alfresa-pharma-stallergenes-greer-dbv-techno]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: https://www.delveinsight.com/
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.